Domain Not Resolving

Google Maps

Font Awesome

reCAPTCHA

Cloudflare CDN

CrUX Dataset

Google Universal Analytics

Cloudflare JS

CDN JS

CrUX Top 50m

Business Management

Craig Johnstone

Chief Business Officer

Matthias Evers

CMO Manager

Sara Mitchell

Executive Vice President, ERP Owner & Transformation Lead

Toni Martin

Werner Lanthaler

Executive Vice President, Head of Molecular Discovery

Adam Davenport

SVP Academic Partnerships and Site Head, Dorothy Crowfoot Hodgkin Campus (Abingdon)

Adam Stoten

Senior Vice President, Infectious Diseases

Anna Upton

VP, Head of Engineering & Facilities Management

Barry Darker

SVP, Head of Global Health, Safety & Environment

Chris Lea

Hubert Birner

Michael Sela

Manfred Eigen

Co-Founder

Heinrich M. Schulte

Enno Spillner

Chief Financial Officer

Chief Operating Officer

Cord Dohrmann

CSO & Managment board member

Dimitar Hristozov

Group Leader & Research Informatics

Freimut Leidenberger

Rudolf Rigler

Sanofi is a healthcare company that provides treatments and the protection of life-saving vaccines.

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.

Germany Companies With More Than 500 Employees

Europe, Middle East, and Africa (EMEA) Public Companies With More Than 100 Employees

Investors Active in Ireland

Investors Active in Greater Seattle Area

Evotec is a drug discovery alliance and development partnership rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licencing of innovative drug candidates, and consulting arrangements.

Bill & Melinda Gates Foundation

Grant - Evotec

Open Philanthropy

European Investment Bank

Post-IPO Debt - Evotec

German Federal Ministry of Education and Research

Mubadala

Post-IPO Equity - Evotec

CARB-X

Computer and Software Services and Scientific Services

Hamburg

Germany

Europe

Evotec

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Evotec and Bristol Myers Squibb expand proteomics partnership

Why Is Evotec Stock Gaining Today?

Eccogene gets $60M from AstraZeneca; Evotec also records milestone with BMS

Evotec and Nospharm patent odilorhabdin analogues for bacterial infections

Deutsche Bank Research reads Evotec 'Sell' - Target 4 Euro

Evotec slips after Jefferies cuts on uncertain strategy, market recovery timing

Evotec and Novo Nordisk forge technology development partnership

Evotec and Novo Nordisk Enter into Technology Development...

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

United States

North America

France

United Kingdom

Switzerland

HTML5

Lightbox

Office 365

Google Analytics

Comodo PositiveSSL Certificates

Fonts.com

jQuery

Matomo (Formerly Piwik)

Vimeo

Thawte SSL

Evotec owns Evotec Neurosciences

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 11:28 AM	d7982876
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 11:28 AM	005ffc96
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	902ed215
crunchbase profile	general	Oct 30, 2024 1:36 PM	de976744
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	f8dbb80e
peers	general
news basic	general	Mar 8, 2024 11:28 AM	3c67769c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:EVOTEC

Evotec SE

Last Close

8.50

25/11 09:24

Market Cap

1.59B

Beta: -

Volume Today

564.94K

Avg: -